Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
IQVIA's weekly prescription tracker for Foundayo (orforglipron) hit approximately 17,000 prescriptions for the week ending May 15, 2026, per Citi's Friday client note — Lilly's first above-15,000 weekly print since the April 6 launch. The week-by-week trajectory: 1,390 (Week 1), 3,707 (Week 2), 5,612 (Week 3), 7,335 (Week 4), 10,248 (Week 5), and ~17,000 in the new print. Novo Nordisk's Wegovy pill recorded roughly 142,000 prescriptions in the same week — the trajectory gap is narrowing as Foundayo's PBM coverage activates at the largest US plans but still remains 8.3x the Foundayo volume. Citi maintains $146M Foundayo Q2 revenue and $1.6B 2026 full-year estimates; the IQVIA print supports the trajectory. Lilly's late-May TV-advertising launch may amplify the next leg of Foundayo growth heading into mid-June.
ASCO will hold an embargoed virtual press briefing for credentialed media on Tuesday May 26 to preview Late-Breaking Abstracts being presented during the Annual Meeting that opens Friday May 29 in Chicago. Late-Breaking Abstracts are submitted after the standard abstract deadline and contain data that would not have been available at the regular submission cycle — typically the highest-impact data of the meeting. The briefing covers presentations across the full ASCO program including the peptide-oncology slate that landed in the May 21 abstract release: Bicycle Therapeutics' Duravelo-2 Phase 2 (65% ORR/58% BICR-confirmed), Avacta's AVA6000 Phase 1a/1b in salivary gland cancer (90% disease control rate), Sapience Therapeutics' lucicebtide Phase 2 GBM, BriaCell's Bria-IMT 16.6-month Phase 2 OS, Corbus Pharmaceuticals' CRB-701 Nectin-4 ADC, and Crinetics' CRN09682 SSTR2 NDC BRAVESST2. The May 26 embargo lifts late afternoon to feed press coverage into the Wednesday-Thursday cycle.
The Memorial Day week landing pad in the medical-conference calendar is unusually peptide-heavy. Monday May 25 is the US Memorial Day federal holiday. EASL 2026 (European Association for the Study of the Liver) opens Wednesday May 27 in Barcelona running through Saturday May 30, with Novo Nordisk's ESSENCE Phase 3 liver-safety analyses, Eli Lilly's retatrutide MASLD Phase 3 enrollment status, Boehringer survodutide SYNCHRONIZE-1 forward-look, and MetaVia vanoglipel + resmetirom MASH preclinical work anchoring the peptide-relevant program. ASCO 2026 (American Society of Clinical Oncology) opens Friday May 29 in Chicago running through Tuesday June 2 with the peptide-oncology slate landing across all five days. Combined, the two meetings concentrate the most peptide-mechanism data of any week in 2026 — MASH plus oncology back-to-back. Practitioner press will be split across the two meetings.
The Sunday coverage cycle on Lilly's Thursday TRIUMPH-1 readout settled into broadly favorable consensus. Leerink's David Risinger characterized the data as 'raising the bar for future novel obesity drug developers'; RBC Capital's Trung Huynh framed it as a 'clean win for Lilly'; Dan Skovronsky (Lilly CSO) called 30% weight loss 'an incredible number to see — we haven't seen that level of weight loss before with these kinds of medicines.' Mainstream press coverage — NPR, BioPharma Dive, CNBC, Good Morning America — uniformly led with the bariatric-surgery-territory framing (45.3% of 12 mg participants reaching ≥30% weight loss). The dysesthesia signal (12.5% at 12 mg) registered in pharma-industry coverage and analyst commentary but received minimal mainstream-press attention. The TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + CVD) readouts later in 2026 are the next inflection points; the NDA filing follows in Q4 2026 or Q1 2027.
Cumulative US Wegovy pill prescriptions, as disclosed in Novo Nordisk CEO Maziar Doustdar's May 14 commentary (>1M) and EVP Larsen's May 18 commentary on CNBC (>2M), continued to trend upward through the Memorial-Day-week lead-in. Weekly Wegovy pill volume of approximately 142,000 for the week ending May 15 — slightly above the prior week's 137,000 after the brief mid-May decline — suggests cumulative US prescriptions are now in the 2.1-2.15M range. The Wegovy pill launch (January 5, 2026) trajectory continues to outpace the comparable Wegovy injectable launch (June 2021), positioning Novo for the projected H2 2026 EU launches in UK, Germany, and Denmark. The Wegovy HD (7.2 mg injectable) CHMP positive opinion announced May 22 adds the high-dose franchise to the EU portfolio.
Day-after analyst commentary on Lilly's Thursday TRIUMPH-1 topline split favorably across major sell-side and management voices. Leerink Partners' David Risinger wrote that 'tolerability and substantial weight loss shown by retatrutide is raising the bar for future novel obesity drug developers,' a framing that lands at the higher end of the analyst spectrum after William Blair's tolerability-confined assessment Thursday. RBC Capital Markets' Trung Huynh characterized the readout as a 'clean win for [Lilly]' citing the clean safety profile plus best-in-class efficacy across all three doses. Dan Skovronsky, Lilly's chief scientific and product officer, told CNBC over the weekend that 30% weight loss in the BMI ≥35 extension is 'an incredible number to see — we haven't seen that level of weight loss before with these kinds of medicines.' The Saturday-Sunday news-cycle handling has settled into broadly favorable territory.
The European Association for the Study of the Liver (EASL) Congress 2026 opens Wednesday May 27 in Barcelona with a heavy peptide-MASH slate. Novo Nordisk's ESSENCE Phase 3 program leads with liver-safety subgroup analyses (Japanese MASH cohort, women in menopause), building on the August 2025 FDA approval of semaglutide for MASH-with-fibrosis. Eli Lilly's retatrutide MASLD Phase 3 (NCT06859268) is enrolling on the 86% Phase 2 liver-fat reduction baseline. Boehringer Ingelheim survodutide SYNCHRONIZE-1 Phase 3 MASH data is expected late 2026 with positive results potentially establishing the GLP-1/glucagon dual agonist as standard of care alternative to semaglutide. MetaVia's vanoglipel (DA-1241, GPR119 agonist) Phase 2a + resmetirom combination work presented at ECO 2025 anchors the combination-MASH therapy thesis. The EASL plenaries plus the May 21 TRIUMPH-1 readout reframe MASH as a peptide-mechanism battleground rather than a single-drug indication.
TRIUMPH-1 reported 45.3% of participants on the 12 mg dose reached ≥30% weight loss — historically the threshold associated with bariatric surgery outcomes (sleeve gastrectomy averages 25-30%, Roux-en-Y gastric bypass 30-35% at 1-2 years). The data point is the most consequential single statistic from the TRIUMPH-1 readout because it reframes the bariatric-referral conversation that anchors severe-obesity care. For patients with BMI 35-40 with comorbidities (the broadest bariatric-eligible population), pharmacological 30% weight loss closely approximates the surgical outcome without the irreversible anatomical changes, perioperative mortality (~0.1% gastric bypass), nutritional-deficiency monitoring requirements, or psychiatric adjustment patterns that follow bariatric procedures. Bariatric surgery centers' patient-referral volume began softening in 2024-2025 as Wegovy and Zepbound scaled; retatrutide's TRIUMPH-1 data accelerates that trend. The American Society for Metabolic and Bariatric Surgery (ASMBS) and the Obesity Society will likely revisit referral algorithms ahead of retatrutide's late-2027 launch.
ASCO 2026 in Chicago opens Friday May 29 with the peptide-oncology calendar now fully fixed. Thursday May 29 4:57 PM CDT: Corbus CRB-701 Nectin-4 ADC oral session in cervical cancer. Friday May 30 4:30 PM CDT: Corbus CRB-701 HNSCC poster. Saturday May 30: BriaCell Bria-IMT three posters in metastatic breast cancer. Sunday May 31: Bicycle Therapeutics zelenectide pevedotin Phase 1 Duravelo-1 monotherapy update poster; Avacta AVA6000 FAP-Dox Phase 1a/1b in salivary gland cancers poster session. Monday June 1 8:30-8:36 AM CT: Bicycle Therapeutics Duravelo-2 oral abstract (Abstract 4516). Monday June 1: Sapience Therapeutics lucicebtide poster session for newly-diagnosed GBM. The peptide-oncology cohort is the largest single-meeting concentration of peptide-mechanism oncology data in recent ASCO history.
Six weeks ahead of the FDA's June 29 closing date for public comments on the April 30 503B bulks-list proposal excluding semaglutide, tirzepatide, and liraglutide, the compounded-GLP-1 telehealth segment has settled into a defensive pricing structure. Ozari Health's May 19 launch at $86/month compounded semaglutide and $120/month compounded tirzepatide established the floor; comparable platforms have held prices steady at $99-249/month rather than competing further on price. The Saturday market sentiment is split: bull case is that the FDA's final determination could grandfather existing 503A patients under a transition window, leaving cash-pay compounded GLP-1 viable through 2027; bear case is that the BSR Intelligence-documented 90% YoY drop in compounded semaglutide shipments accelerates as 503B compounding ends, with only the smallest-volume 503A pharmacies remaining. Patient migration toward branded Wegovy via Novo's Hims & Hers branded-distribution channel (125K shipments in six weeks) is the natural off-ramp.
Day-after analyst reaction to Lilly's May 21 TRIUMPH-1 topline split between efficacy enthusiasm and tolerability caution. LLY shares rose roughly 1% in Thursday premarket trading. William Blair noted that retatrutide's 11.3% discontinuation rate on 12 mg plus the dysesthesia signal (skin tingling, 12.5% of 12 mg participants — a finding not reported in Phase 2 data) probably confines the drug to higher-BMI patient populations, with tirzepatide remaining the volume agent at the moderate-BMI tier. BMO Capital Markets specifically flagged the dysesthesia signal as worth monitoring in subsequent readouts and the TRIUMPH-4 follow-on detail. Manak Mahmood at Pharma Intelligence framed the data as 'very impressive' but noted ADA 2026 full data presentation in two weeks will be critical for the obesity-market positioning. The GI side-effect profile at 12 mg — nausea 42.4%, vomiting 25.3%, diarrhea 32.0% — is the tolerability gap that prescribers will weigh against the efficacy gain over tirzepatide.
Hims & Hers Health announced May 18 the pricing of an upsized $350M aggregate principal amount of 0.00% convertible senior notes due 2032, with settlement May 21. Initial conversion rate is 33.8590 shares of Class A common stock per $1,000 principal — a conversion price of approximately $29.53 per share, representing a 32.5% premium over the $22.29 close on May 18. The capped call cap price was set at approximately $50.15 per share (125% premium). Initial purchasers granted an option to buy up to an additional $52.5M in notes within 13 days. Proceeds support international expansion strategy and the proposed acquisition of Eucalyptus (Australian-based digital health platform with peptide and weight-management presence in Australia, UK, and Germany) expected to close mid-2026. The convertible structure preserves cash for the international rollout while the Novo Nordisk branded distribution partnership scales US Wegovy supply.
Industry commentary May 22 framed Novo Nordisk's strategic response to retatrutide's TRIUMPH-1 readout as a two-track amylin strategy. CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) is the near-term play — Phase 3 REDEFINE-1 and REDEFINE-2 complete, FDA filing under review with decision expected late 2026, and Novo positioning the safety profile as the competitive edge after REDEFINE-4 missed non-inferiority versus tirzepatide 15 mg in February 2026. Amycretin (dual GLP-1/amylin agonist) is the long-term bet — AMAZE-12 Phase 3 began recruiting May 18 testing the dual agonist for weight maintenance, with Phase 1 results showing 22% weight loss at 36 weeks weekly subcutaneous and 13.1% at 12 weeks oral. The CagriSema higher-dose Phase 3 starts H2 2026; REDEFINE-11 reads out H1 2027. Combined, the amylin axis is structurally Novo's most direct response to Lilly's triple-agonist mechanism — adding amylin tone (slower gastric emptying, satiety persistence, weight-maintenance) rather than competing on glucagon-driven energy expenditure.
A May 21 Research and Markets report projected the global GLP-1 receptor agonist weight loss drug market expanding from $15.5B in 2025 to $18.02B in 2026 — a 16.3% compound annual growth rate. The forecast tracks through 2030 and 2035 across major players Novo Nordisk, Eli Lilly, and Pfizer, plus the growing oral GLP-1 segment (Wegovy pill, Foundayo, Structure Therapeutics' aleniglipron entering Phase 3). By 2020 roughly 4 million people were on GLP-1s; by 2026 that estimate has reached 30 million. The market data is the formal backdrop for the broader 2026 obesity-pharmacology conversation: GLP-1 alone is now larger than the 2024 oncology drug class's largest single product. The IQVIA peptide-CDMO capacity-build wave (Bachem, PolyPeptide, CordenPharma SPPS expansions through 2028) and the Lilly $4.5B Lebanon Indiana investment lean directly into the demand projection.
Regeneron Pharmaceuticals and Parabilis Medicines announced May 18 a strategic research collaboration to discover and develop antibody-Helicon conjugates (AHCs) — a novel modality combining Regeneron's antibody platform with Parabilis's Helicon stabilized helical peptide technology. Deal structure: $50M upfront, $75M equity commitment, and up to $2.2B in development and regulatory milestones across an initial five targets, plus tiered royalties. The Helicon platform locks peptides into their bioactive helical conformation, enabling targeting of historically undruggable protein-protein interaction surfaces that small molecules cannot access. The conjugate format pairs antibody-mediated tissue homing with peptide payload delivery — an extension of the broader peptide-drug-conjugate field that included Bicycle Therapeutics' bicyclic peptide-MMAE conjugates and Avacta's FAP-activated PDCs. The deal is the largest single peptide-platform partnership announced in 2026.
ASCO 2026 abstract text released at 5 PM ET Thursday, ahead of the May 29-June 2 Chicago meeting. The peptide-oncology data landed simultaneously across the previously-announced slate. Bicycle Therapeutics released Duravelo-2 Phase 2/3 interim data on zelenectide pevedotin (BT8009) plus pembrolizumab in 1L locally advanced/metastatic urothelial cancer. Avacta released AVA6000 Phase 1b data in salivary gland cancers. BriaCell released final Phase 2 Bria-IMT survival data plus biomarker analyses from the ongoing Phase 3. BioVaxys's MVP-S PESCO Phase 1B/2 ovarian cancer abstract landed. Crinetics CRN09682 SSTR2 NDC BRAVESST2 abstract emerged. Pfizer released 40+ company-sponsored, investigator-sponsored, and collaborative oncology abstracts including three late-breaking sessions. The peptide-oncology cohort is the largest single ASCO presence in recent meeting history.
5W Public Relations published the fourth installment of its AI Visibility Index, finding two manufacturers — Novo Nordisk and Eli Lilly — account for nearly 100% of GLP-1-class citations inside ChatGPT, Claude, Perplexity, and Google AI Overviews. Five products — Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda — capture about 57% of all weight-loss-and-metabolic-health category citations. Founder Ronn Torossian attributes the citation moat to peer-reviewed clinical data cadence, named-author editorial coverage, and regulatory events treated as content events, with content velocity outpacing the broader news cycle.
20n Bio announced a $7.5 million Seed+ round May 20 led by a strategic industry investor with participation from a London-based life-sciences VC. Proceeds advance the company's high-throughput cyclic peptide platform — which screens libraries of up to 10 trillion sequences — and integrate AI into the discovery workflow. 20n is a Bayer Co.Lab resident and has a January 2026 long-term partnership with Yantai Lannacheng Biotechnology to develop next-generation radionuclide drug conjugates, leveraging Lannacheng's clinical translation and manufacturing for precision oncology programs.